What is HC Wainwright’s Forecast for INO Q3 Earnings?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – HC Wainwright raised their Q3 2026 earnings per share estimates for Inovio Pharmaceuticals in a report issued on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.20) per share for the quarter, up from their previous forecast of ($0.24). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.73) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.21) EPS.

Several other research analysts also recently commented on the company. Jefferies Financial Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and raised their target price for the stock from $1.80 to $3.00 in a research note on Thursday, August 13th. Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Finally, Zacks Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $3.17.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $1.20 on Monday. The business’s fifty day moving average is $1.03 and its 200 day moving average is $1.29. The firm has a market cap of $124.08 million, a price-to-earnings ratio of -1.32 and a beta of 1.52. Inovio Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of INO. Millennium Management LLC increased its holdings in shares of Inovio Pharmaceuticals by 468.7% in the 3rd quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock worth $4,616,000 after buying an additional 1,625,653 shares during the last quarter. Eversept Partners LP bought a new stake in shares of Inovio Pharmaceuticals during the 1st quarter worth $1,802,000. Vanguard Group Inc. lifted its holdings in shares of Inovio Pharmaceuticals by 35.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after acquiring an additional 703,727 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new position in Inovio Pharmaceuticals in the second quarter worth $14,946,000. Finally, Danske Bank A S grew its position in Inovio Pharmaceuticals by 79.0% in the second quarter. Danske Bank A S now owns 577,477 shares of the biopharmaceutical company’s stock worth $23,694,000 after acquiring an additional 254,954 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.